TransCode Therapeutics (NASDAQ:RNAZ) Trading Up 0.6% – Should You Buy?

TransCode Therapeutics Inc. (NASDAQ:RNAZ)’s stock price traded up 0.6% on Thursday . The stock traded as high as $8.82 and last traded at $8.74. 1,541 shares were traded during trading, a decline of 83% from the average session volume of 8,939 shares. The stock had previously closed at $8.69.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $280.00.

TransCode Therapeutics Stock Up 0.6%

The company has a market cap of $8.04 million, a PE ratio of -0.32 and a beta of 1.49. The business has a 50-day simple moving average of $9.59 and a 200-day simple moving average of $9.82.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.